-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: Family Practice
Med Prep Consulting Compounded Products Recall
Translation Med Prep Consulting Inc. Compounded Products: Recall – Potential Mold Contamination AUDIENCE: Risk Manager, Pharmacy, Family Practice ISSUE: Med Prep Consulting, Inc. notified the public that it is recalling all lots of all products compounded at its facility, due … Continue reading
Posted in Family Practice, FDA 2013, FDA Recall, Pharmacy, Risk Manager
Tagged Compounded Products, drug risks, Family Practice, FDA recall, Med Prep Consulting, Med Prep Consulting Compounded Products Recall, Pharmacy, Recall, Risk Manager
Comments Off
Azithromycin Zithromax or Zmax Drug Safety Communication
TranslationAzithromycin (Zithromax or Zmax): Drug Safety Communication – Risk of Potentially Fatal Heart Rhythms AUDIENCE: Family Practice, Patient, Pharmacy, Health Professional ISSUE: FDA is warning the public that azithromycin (Zithromax or Zmax) can cause abnormal changes in the electrical activity … Continue reading
Zolpidem Containing Products Drug Safety Communication
TranslationZolpidem Containing Products: Drug Safety Communication – FDA Requires Lower Recommended Doses Including Ambien, Ambian CR, Edluar, and Zolpimist AUDIENCE: Family Practice, Health Professional, Patient ISSUE: FDA is notifying the public of new information about zolpidem, a widely prescribed insomnia … Continue reading
Posted in Family Practice, FDA 2013, FDA Safety Communication, Healthcare Professionals, Patients
Tagged Ambian CR, Ambien, drug risks, Drug Safety Communication, Edluar, Family Practice, Health Professional, Patient, Safety Communication, Zolpidem Containing Products, Zolpidem Containing Products Drug Safety Communication, Zolpimist
Comments Off
Chantix Varenicline Safety Communication
TranslationChantix (Varenicline): Safety Communication – Updated Safety Review On The Risk of Cardiovascular Adverse Events AUDIENCE: Family Practice, Cardiology, Patient ISSUE: FDA is informing the public about the results of a large, combined analysis (called a meta-analysis) of clinical trials … Continue reading
Posted in Cardiology, Family Practice, FDA Safety Communication, Patients
Tagged Cardiology, Chantix, Chantix Varenicline Safety Communication, drug risks, Drug Safety Communication, Family Practice, FDA notice, Patient, Safety Communication, Varenicline
Comments Off
St Jude Medical Riata Implantable Cardioverter Defibrillator ICD Leads
Translation St. Jude Medical Riata Implantable Cardioverter Defibrillator (ICD) Leads: Safety Communication – Premature Insulation Failure [Posted 08/16/2012] AUDIENCE: Cardiology, Radiology, Surgery, Family Practice ISSUE: The Food and Drug Administration (FDA) is providing information and recommendations regarding safety concerns with the … Continue reading
Posted in Cardiology, Family Practice, FDA 2012, FDA Notice, Radiology, Surgery
Tagged Cardiology, Cardioverter Defibrillator, drug risks, Family Practice, FDA notice, ICD Leads, Implantable, Radiology, St Jude Medical Riata, St Jude Medical Riata Implantable Cardioverter Defibrillator ICD Leads, Surgery
Comments Off
Introvale levonorgestrel and ethinyl estradiol Tablets Recall
TranslationIntrovale (levonorgestrel and ethinyl estradiol) Tablets: Recall – Packaging Flaw AUDIENCE: Consumer, Pharmacy ISSUE: Sandoz notified the public that it issued a voluntary recall of 10 lots of its generic oral contraceptive Introvale in the US, following a recent report … Continue reading
Posted in Consumer Products, FDA 2012, FDA Recall, Pharmacy
Tagged Birth Control Pills, Consumer, Consumer Products, drug risks, ethinyl estradiol, extended-cycle oral contraceptive, Family Practice, FDA recall, Introvale, Introvale levonorgestrel and ethinyl estradiol Tablets Recall, levonorgestrel, Pharmacy, Recall, Sandoz, tablets
Comments Off
FDA Warning Brilliant Blue G
TranslationCertain Compounded Drugs from Franck’s: FDA Issues Second Warning to Physicians Brilliant Blue G (BBG) Triamcinolone AUDIENCE: Eye Care, Family Practice, Pharmacy ISSUE: FDA has received additional reports of fungal endophthalmitis (eye infections) in patients who were given Brilliant Blue … Continue reading
Posted in Eye Care, Family Practice, FDA 2012, FDA Warning, Pharmacy
Tagged Brilliant Blue G, Eye Care, eye infections, Family Practice, FDA warning, fungal endophthalmitis, Pharmacy, Triamcinolone
Comments Off
Birth Control Pills Health Risks
TranslationBirth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots AUDIENCE: OBGYN, Family Practice, Patient ISSUE: FDA has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots … Continue reading
Posted in Family Practice, FDA 2012, FDA Label Change, OBGYN, Patients
Tagged Birth Control Pills, Birth Control Pills Health Risks, Drospirenone, drug risks, Family Practice, FDA notice, Health Risks, higher risk for blood clots, OBGYN, safety label changes
Comments Off
Altuzan bevacizumab Counterfeit Product
TranslationAltuzan (bevacizumab): Counterfeit Product – Contains no Active Ingredient ISSUE: FDA lab tests have confirmed that a counterfeit version of Roche’s Altuzan 400mg/16ml (bevacizumab),an injectable cancer medication, found in the U.S. contains no active ingredient. Even if the identified … Continue reading
Posted in Family Practice, FDA 2012, FDA Recall, FDA Warning, Healthcare Professionals, Oncology, Patients
Tagged Altuzan, Altuzan bevacizumab Counterfeit Product, bevacizumab, Cancer Drugs, Counterfeit Product, drug risks, Family Practice, FDA recall, FDA warning, Oncology, or Ban Dune Marketing Inc, Recall, Richards Pharma, Richards Services, Roche’s Altuzan 400mg/16ml, Unapproved Drug, Warwick Healthcare Solutions
Comments Off
Statins and HIV or Hepatitis C Drugs Drug Safety Communication
TranslationStatins and HIV or Hepatitis C Drugs: Drug Safety Communication – Interaction Increases Risk of Muscle Injury AUDIENCE: Infectious Disease, Family Practice, Patients ISSUE: FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. … Continue reading
Posted in Family Practice, FDA 2012, FDA Safety Communication, Infectious Disease, Patients
Tagged drug interactions, drug risks, Drug Safety Communication, Family Practice, FDA notice, hiv, HIV or Hepatitis C Drugs, Infectious Disease, myopathy, Patients, protease inhibitors, Statins, Statins and HIV or Hepatitis C Drugs Drug Safety Communication
Comments Off